{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:53:56Z","timestamp":1776236036721,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti-T-lymphocyte globulin (ATLG) is commonly administered to reduce graft-versus-host disease (GVHD) in allogeneic stem cell transplantation (allo-SCT). However, the optimal ATLG dose in matched-sibling-donor (MSD) peripheral blood stem-cell transplantation (PBSCT) remains uncertain. We compared two ATLG doses (15\u2009mg\/kg vs. 30\u2009mg\/kg) in the MSD-PBSCT setting to assess allo-SCT outcomes. In this single-center retrospective study, we included 165 consecutive patients with hematologic malignancies who underwent MSD-PBSCT. Of these, 71 received 15\u2009mg\/kg ATLG (ATLG-15), and 94 received 30\u2009mg\/kg ATLG (ATLG-30). ATLG-15 was associated with earlier leukocyte (median 11 vs. 12 days,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004) and platelet engraftment (median 12 vs. 15 days,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0002). Moderate\/severe chronic GVHD at 2 years was significantly higher with ATLG-15 (43% vs. 28%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.045), with no difference in OS, PFS, NRM, or CIR. In multivariable analysis, ATLG-30 was associated with improved GRFS (HR 0.47,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). After propensity score matching, GRFS and all-grade cGVHD remained significantly better with ATLG-30 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.047), with a trend toward reduced moderate\/severe cGVHD (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.067). In AML\/MDS patients not receiving TBI (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009108), moderate\/severe cGVHD remained lower with ATLG-30 (19% vs. 38%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039). Our study suggests that ATLG-30 in MSD-PBSCT reduces moderate\/severe cGVHD and improves GRFS.\n                  <\/jats:p>","DOI":"10.1038\/s41409-025-02761-5","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:56:00Z","timestamp":1769000160000},"page":"426-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-3840","authenticated-orcid":false,"given":"Radwan","family":"Massoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny","family":"Klyuchnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroly Bohorquez","family":"Manjarres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Zeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Langebrake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3301-0059","authenticated-orcid":false,"given":"Adrin","family":"Dadkhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusudan","family":"Sabauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-1011","authenticated-orcid":false,"given":"Christian","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Sch\u00e4fersk\u00fcpper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska E.","family":"Marquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maraike","family":"Harfmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Oechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4546-7650","authenticated-orcid":false,"given":"Gunnar","family":"Weise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Rathje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherina","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-1309","authenticated-orcid":false,"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-1847","authenticated-orcid":false,"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2761_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813\u201326. https:\/\/doi.org\/10.1056\/NEJMra052638.","journal-title":"N Engl J Med"},{"key":"2761_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"2761_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donor, s. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"2761_CR4","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/S2352-3026(18)30214-X","volume":"6","author":"F Bonifazi","year":"2019","unstructured":"Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol. 2019;6:e89\u2013e99. https:\/\/doi.org\/10.1016\/S2352-3026(18)30214-X.","journal-title":"Lancet Haematol"},{"key":"2761_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. lancet Oncol. 2009;10:855\u201364.","journal-title":"lancet Oncol"},{"key":"2761_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"2761_CR7","doi-asserted-by":"publisher","first-page":"96460","DOI":"10.18632\/oncotarget.20878","volume":"8","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Merli P, Bertaina A. Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation. Oncotarget. 2017;8:96460\u20131. https:\/\/doi.org\/10.18632\/oncotarget.20878.","journal-title":"Oncotarget"},{"key":"2761_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbmt.2008.05.023","volume":"14","author":"F Ayuk","year":"2008","unstructured":"Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2008;14:913\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2008.05.023.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2761_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","volume":"57","author":"R Massoud","year":"2022","unstructured":"Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, et al. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transpl. 2022;57:1548\u201355. https:\/\/doi.org\/10.1038\/s41409-022-01666-x.","journal-title":"Bone Marrow Transpl"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol blood marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol blood marrow Transpl"},{"key":"2761_CR11","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S2352-3026(20)30394-X","volume":"8","author":"R Shouval","year":"2021","unstructured":"Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8:e205\u2013e215.","journal-title":"Lancet Haematol"},{"key":"2761_CR12","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2761_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2761_CR14","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u2013e167.","journal-title":"Lancet Haematol"},{"key":"2761_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","volume":"55","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Rubio M-T, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone marrow Transpl. 2020;55:1093\u2013102.","journal-title":"Bone marrow Transpl"},{"key":"2761_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.exphem.2008.03.011","volume":"36","author":"F Ayuk","year":"2008","unstructured":"Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol. 2008;36:1047\u201354. https:\/\/doi.org\/10.1016\/j.exphem.2008.03.011.","journal-title":"Exp Hematol"},{"key":"2761_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.bmt.1704135","volume":"32","author":"M Schleuning","year":"2003","unstructured":"Schleuning M, G\u00fcnther W, Tischer J, Ledderose G, Kolb H. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone marrow Transpl. 2003;32:243\u201350.","journal-title":"Bone marrow Transpl"},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00277-021-04521-z","volume":"100","author":"S Butera","year":"2021","unstructured":"Butera S, Cerrano M, Brunello L, Dellacasa CM, Faraci DG, Vassallo S, et al. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. Ann Hematol. 2021;100:1837\u201347.","journal-title":"Ann Hematol"},{"key":"2761_CR19","first-page":"2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood, J Am Soc Hematol. 2001;98:2942\u20137.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2761_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/bmt.2013.191","volume":"49","author":"Y Wang","year":"2014","unstructured":"Wang Y, Fu H, Liu D, Xu L, Zhang X, Chang Y, et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone marrow Transpl. 2014;49:426\u201333.","journal-title":"Bone marrow Transpl"},{"key":"2761_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/sci.2017.05.02","volume":"4","author":"C De Koning","year":"2017","unstructured":"De Koning C, Admiraal R, Nierkens S, Boelens JJ. Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig. 2017;4:38.","journal-title":"Stem Cell Investig"},{"key":"2761_CR22","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-014-1742-z","volume":"140","author":"A Mensen","year":"2014","unstructured":"Mensen A, Na I-K, H\u00e4fer R, Meerbach A, Schlecht M, Pietschmann M-L, et al. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. J cancer Res Clin Oncol. 2014;140:1971\u201380.","journal-title":"J cancer Res Clin Oncol"},{"key":"2761_CR23","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194\u2013e203.","journal-title":"Lancet Haematol"},{"key":"2761_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bbmt.2010.02.027","volume":"16","author":"PJ Podgorny","year":"2010","unstructured":"Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transpl. 2010;16:915\u201326. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.027.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2761_CR25","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, randomized, double-blind, phase III clinical trial of anti\u2013T-lymphocyte globulin to assess impact on chronic graft-versus-host disease\u2013free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35:4003\u201311.","journal-title":"J Clin Oncol"},{"key":"2761_CR26","first-page":"265. e261","volume":"28","author":"MQ Salas","year":"2022","unstructured":"Salas MQ, Pasic I, Remberger M, Novitzky-Basso I, Law AD, Lam W, et al. Improving safety and outcomes after allogeneic hematopoietic cell transplantation: a single-center experience. Transpl Cell Ther. 2022;28:265. e261\u2013265. e269.","journal-title":"Transpl Cell Ther"},{"key":"2761_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone marrow Transpl. 2020;55:126\u201336.","journal-title":"Bone marrow Transpl"},{"key":"2761_CR28","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1182\/bloodadvances.2023012469","volume":"8","author":"N Khera","year":"2024","unstructured":"Khera N, Ailawadhi S, Brazauskas R, Patel J, Jacobs B, Ustun C, et al. Trends in volumes and survival after hematopoietic cell transplantation in racial\/ethnic minorities. Blood Adv. 2024;8:3497\u2013506.","journal-title":"Blood Adv"},{"key":"2761_CR29","first-page":"697. e691","volume":"29","author":"MP Pereira","year":"2023","unstructured":"Pereira MP, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transpl Cell Ther. 2023;29:697. e691\u2013697. e610.","journal-title":"Transpl Cell Ther"},{"key":"2761_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41409-023-01997-3","volume":"58","author":"T Konuma","year":"2023","unstructured":"Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, et al. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?. Bone Marrow Transpl. 2023;58:893\u2013906.","journal-title":"Bone Marrow Transpl"},{"key":"2761_CR31","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R, et al. Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol. 2024;42:3277\u201386.","journal-title":"J Clin Oncol"},{"key":"2761_CR32","first-page":"103499","volume":"73","author":"L Lazzari","year":"2025","unstructured":"Lazzari L, Catalano G, Bruno A, Sannipoli D, Lupo-Stanghellini MT, Peccatori J, et al. Post-transplant cyclophosphamide in matched donor transplantation: are we there yet?. Curr Res Transl Med. 2025;73:103499.","journal-title":"Curr Res Transl Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02761-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:19:50Z","timestamp":1775571590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02761-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02761-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NK has received honoraria and consulting fees from Neovii, Novartis, MSD, Sanofi, Kite\/Gilead, Kyverna, Medac, Jazz Pharmaceuticals, and Bristol Myers Squibb (BMS). All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}